Home >> Protein Tyrosine Kinase >> EGFR >> EGFR Inhibitors >> 
United States (Change Country)

CI-1033 (Canertinib)

Catalog No. S1019 5 5 6 Customer Review(s) Product Citations4 Product Citation(s)
Price Availability Quantity
$ 70 Yes
$ 170 Yes
$ 270 Yes
$ 670 Yes
 
processing...
Free Overnight Delivery on all orders over $ 500.

Order CI-1033 (Canertinib) now
and get it on

CI-1033 (Canertinib) Chemical Structure

Bio Information

CI-1033 (Canertinib) is an orally bioavailable irreversible Pan-erbB tyrosine kinase inhibitor, targeting EGFR with IC50 of 0.8, 19 and 7 nM for EGFR, HER-2 and ErbB-4, respectively. It effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT. inhibitor, is a clinically promising agent that is active against all four members of the erbB receptor tyrosine kinase family. In vitro studies of human cancer cell lines indicate that CI-1033 results in prompt, potent, and sustained inhibition of tyrosine kinase activity. This inhibition is highly selective for erbB1 (epidermal growth factor receptor), erbB2, erbB3, and erbB4 without inhibiting tyrosine kinase activity of receptors such as platelet-derived growth factor receptor, fibroblast growth factor receptor, and insulin receptor, even at high concentrations. [1][2]

References:

[1] Clin Cancer Res 2004 Nov 1;10(21):7112-20

[2] Semin Oncol 2001 Oct;28(5 Suppl 16):80-5

Chemical Information

Molecular Weight (WM): 485.94
Formula:

C24H25ClFN5O3

Solubility(R.T.:25°C): DMSO 2mg/mL 
Water <1mg/mL 
Ethanol 9mg/mL 

Quality Control

View current batch:
H-NMR HPLC

Research Area

Recommended Screening Libraries

Related Inhibitors

Related Antibodies

CI-1033 (Canertinib) has been referenced in 4 publications.

The fibroblast-derived paracrine factor neuregulin-1 has a novel role in regulating the constitutive color and melanocyte function in human skin.
Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

We have 6 customer reviews of CI-1033 (Canertinib).

  • (6)
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)

Average Customer Review

(6 customer reviews)
  • ;Cell Cycle 8, 13, 2050-2056
    CI-1033 (Canertinib) purchased from Selleck

  • ;Cell Cycle 8, 13, 2050-2056
    CI-1033 (Canertinib) purchased from Selleck

  • ;Dr. Kian Kani of Cedars-Sinai Medical Center
    CI-1033 (Canertinib) purchased from Selleck

  • ;Dr. Zhang of Tianjin Medical University
    CI-1033 (Canertinib) purchased from Selleck

  • Data from [Carcinogenes 2010;31, 1948–1955 ]
    CI-1033 (Canertinib) purchased from Selleck

  • Data from [Carcinogenesis 2010;31, 1948–1955]
    CI-1033 (Canertinib) purchased from Selleck

Our scientific support team are available to answer any questions or queries.
Fill out an inquiry form for CI-1033 (Canertinib) for help.

Quality Matters

This product has been referenced in

Check our customer reviews


Click to enlarge

;Cell Cycle 8, 13, 2050-2056


Click to enlarge

;Cell Cycle 8, 13, 2050-2056

Your Recent History

Keywords:buy CI-1033 (Canertinib) | CI-1033 (Canertinib) supplier | purchase CI-1033 (Canertinib) | CI-1033 (Canertinib) cost | CI-1033 (Canertinib) manufacturer | order CI-1033 (Canertinib) | CI-1033 (Canertinib) distributor